By: Tomas Ronolski - AllPennyStocks.com News

Thursday, October 1, 2015

Nutraceutical products have seen increasing adoption among consumers, especially in the U.S. Nutraceutical products are a combination of nutrition and pharmaceutical products. According to RNCOS Business Consultancy Services, the U.S. nutraceutical industry has been riding the tidal waves for the past few years. The U.S. nutraceutical industry has grown at a swift pace, creating opportunities for players in the industry. RNCOS believes that given the favorable demographics, positive eco-financial dynamics, and rising focus on digital marketing/sales channels, the U.S. nutraceutical market could continue to see significant growth.

RNCOS expects the U.S. nutraceutical market to reach $75.9 billion by 2018. The market is expected to grow at a CAGR of 5% between 2013 and 2018.

The nutraceutical industry can be split into three different segments. The segments are dietary supplements, functional food and functional beverages.

The U.S. nutraceutical industry has a number of players. This morning an emerging player in the nutraceutical space, ImmuDyne (OTCQB:IMMD) announced that its sales continue to improve.

Based in Mount Kisco, New York, ImmuDyne is engaged in the development of proprietary topical and oral delivery technologies, with several new market opportunities. The company is engaged in the manufacture and sale of yeast beta-1,3/1,6 glucan for oral and topical uses.

IMMD announced today that its revenues in the first nine months of 2015 grew to $844,268. For the same period last year, the company had revenue of $554,509. Revenue in the third quarter rose 40% on a year-over-year basis to $279,000. IMMD said that it is looking to capitalize on its strong intellectual property and is also pursuing additional sales and marketing opportunities. At the same time, the company has taken steps to keep expenses under control.

Mark McLaughlin, President and CEO of ImmuDyne, said that the company is now approaching positive cash flow and earnings, and continues to execute on new sales opportunities. McLaughlin further said that with around 30 million shares outstanding and no material debt, any incremental sales growth will be meaningful to the bottom line.

Sven Rohmann, M.D., PhD, MBA, ImmuDyne’s Chief Medical Officer, said that in addition to improved sales reported thus far in 2015, there are significant new market opportunities for the company’s proprietary oral and topical delivery technology. Rohmann further said that the company expects to report on the first application very soon.

Copyright © 2015 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.